GDTC Stock — CytoMed Therapeutics Limited: Cash, EV, Pipeline

Share price

$0.98

Market cap

$11.6M

Cash

$1.6M

Enterprise value

$10.3M

Balance sheet

Cash	$1.6M
Debt	$0.3M
Net cash	$1.3M
Enterprise value	$10.3M
Basic shares	11.7M shares
Fully diluted shares	13.0M shares
Fully diluted market cap	$12.7M
Cash per share	$0.14

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading GDTC daily closes…

Loading price history…

Pipeline assets

CTM-N2D

Phase 1 · Active Modality: allogeneic NKG2DL-targeting CAR-grafted gamma delta T cells

Target NKG2DL

Indications

advanced solid tumors (Phase 1)
hematologic malignancies (Phase 1)

Status note ANGELICA Phase 1 trial. CTM-GDT, CTM-MSC and CTM-NK are named as proprietary products but stages and indications are not disclosed in the filing excerpts.

Per-asset detail extracted from the 20-F filed 2026-03-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2
Lead indication	Cancer
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05302037	Phase 1	Recruiting	Sponsor	CytoMed Therapeutics Pte Ltd	—	Cancer; Malignancy; Refractory Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for CytoMed Therapeutics Pte Ltd on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

GDTC — CytoMed Therapeutics Limited

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials